You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: ELITE ATHLETE PRODUCTS INC Topic: NICHD
PROJECT SUMMARY More than 795,000 individuals suffer from a stroke each year in the United States, making stroke a leading cause of adult disability in the United States and worldwide. More than half of stroke survivors exhibit reduced independence and functional mobility due to stroke-related gait impairments. Despite significant advancements in post-stroke medical care and rehabilitation, curren ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber ReinforcementSBC: SINTX TECHNOLOGIES, INC. Topic: NIAMS
PROJECT SUMMARY—More than 2 million Americans are hospitalized each year with bone fractures, and many more undergo outpatient procedures for fracture reduction and fixation. Some injuries can be treated with closed reduction and splinting or casting to immobilize the bone during healing. However, at some sites, more than half of fractures require open reduction and internal fixation. Despite ad ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: VENOVA TECHNOLOGIES, INC. Topic: NICHD
PROJECT SUMMARY The applicant, Venova Technologies, is a woman-led medical device startup company. Venova Technologies is applying for a Small Business Technology Transfer (STTR) Phase I grant to fund development towards technical milestones that will advance the commercial potential of our patent-pending non-hormonal contraceptive device. Half of pregnancies in the United States are unintended du ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHS
Project Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: MelioLabs Inc. Topic: NICHD
PROJECT SUMMARY Since 2014, Congenital Syphilis (CS) cases in the United States, caused by the transplacental transmission of the bacterium Treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise andgt;185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fe ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: NICHD
Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: GROW BIOMEDICINE LLC Topic: 300
Project Summary We have developed a candidate product that induces colon epithelial repair in ulcerative colitis (UC) models. UC comprises a major type of inflammatory bowel disease and is characterized by chronic and relapsing inflammation in the gastrointestinal (GI) tract. UC develops in the innermost mucosal layer of the distal GI tract in a continuous manner, usually starting at the rectum an ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgerySBC: BIOGRAFT, INC. Topic: NHLBI
Saphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: MIRTECH INC Topic: NHLBI
Project Abstract1.4 million people in the US (2021) have implanted cardioverter-defibrillators (ICDs) of which ~50% will require an MRI scan in their lifetime. All ICDs generate large artifacts in MRI such as signal-voids in cardiac MR (cMR) images, which frequently occur in important pathological (infarcted) regions. Reliable diagnosis of ventricular tachycardia, premature ventricular contraction ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R HaploinsufficiencySBC: COURAGE THERAPEUTICS INC Topic: 102
The melanocortin peptide therapeutic setmelanotide, (ImcivreeTM), is highly effective in the treatment of the rare obesity syndromes, POMC and leptin receptor deficiency. However, the drug is ineffective for the most common syndromic obesity, melanocortin-4 receptor (MC4R) deficiency (MC4R haploinsufficiency), found at a prevalence greater than 1/1000 individuals. Further, the drug is ineffective ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health